title: Effects of erythropoietin on platelet reactivity and thrombopoiesis in humans.
abstract: A recent study in dogs suggested that erythropoietin (EPO) not only promotes the synthesis of increased numbers of reticulated platelets but that these newly produced platelets are hyperreactive compared with controls. Because of the increasing use of EPO in the perioperative setting, we characterized the effects of EPO on platelet reactivity in healthy human volunteers. In a randomized, controlled trial, we studied the effects of EPO on platelet reactivity, thrombopoiesis, and endothelial activation in circumstances similar to those of autologous blood donation. Thirty healthy male volunteers received placebo or EPO (100 or 500 U/kg of body weight given intravenously) three times a week for 2 weeks and underwent phlebotomy on days 8 and 15. Thrombin receptor-activating peptide induced expression of P-selectin, and CD63 increased 2- to 3-fold during EPO treatment. The enhanced platelet reactivity was also reflected by a 50% increase in soluble P-selectin in plasma. Plasma E-selectin levels increased in a dose-dependent fashion by more than 100% during EPO treatment, indicating substantial activation of endothelial cells. A 10% to 20% increase in platelet counts was observed in both EPO groups on day 5. In the placebo group, platelets increased only several days after the first phlebotomy. The increase in platelet counts was not reflected by changes in the amounts of reticulated platelets or circulating progenitor cells. In summary, we found that EPO markedly enhances endothelial activation and platelet reactivity, which may adversely affect patients at cardiovascular risk. However, the increased platelet reactivity could be exploited in patients with platelet dysfunction. (Blood. 2000;95:2983-2989)
authors.affiliation: Department of Clinical Pharmacology-The Adhesion Research Group Elaborating Therapeutics (TARGET), Vienna University School of Medicine, Austria.
authors.forename: P J
authors.initials: PJ
authors.lastname: Stohlawetz
authors.forename: L
authors.initials: L
authors.lastname: Dzirlo
authors.forename: N
authors.initials: N
authors.lastname: Hergovich
authors.forename: E
authors.initials: E
authors.lastname: Lackner
authors.forename: C
authors.initials: C
authors.lastname: Mensik
authors.forename: H G
authors.initials: HG
authors.lastname: Eichler
authors.forename: E
authors.initials: E
authors.lastname: Kabrna
authors.forename: K
authors.initials: K
authors.lastname: Geissler
authors.forename: B
authors.initials: B
authors.lastname: Jilma
mesh_terms: D000328:Adult; D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D015815:Cell Adhesion Molecules / Q000097:blood; D004285:Dogs; D004311:Double-Blind Method; D019040:E-Selectin / Q000097:blood; D004730:Endothelium, Vascular / Q000187:drug effects / Q000502:physiology; D004921:Erythropoietin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D006410:Hematopoiesis / Q000187:drug effects / Q000502:physiology*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D019007:P-Selectin / Q000097:blood; D010919:Placebos; D010976:Platelet Count / Q000187:drug effects; D010980:Platelet Membrane Glycoproteins / Q000032:analysis; D018179:Receptors, Thrombin / Q000502:physiology; D017701:Reticulocyte Count / Q000187:drug effects; D060149:Tetraspanin 30; D013997:Time Factors
chemical_list: D015703:Antigens, CD; C554586:CD63 protein, human; D015815:Cell Adhesion Molecules; D019040:E-Selectin; D006454:Hemoglobins; D009842:Oligopeptides; D019007:P-Selectin; D010919:Placebos; D010980:Platelet Membrane Glycoproteins; D018179:Receptors, Thrombin; D060149:Tetraspanin 30; C096900:thrombin receptor-activating peptide SFLLRNPNDKY; D004921:Erythropoietin